CSLCSLLY -2.30%73 Return-on-Tangible-Equity is 23.92% as of Dec. 2025, which is 66% below its 10-year median of 70.49. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.49 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,205 Biotechnology companies, CSL ranks better than 87.88% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. CSL's annualized net income for the quarter that ended in Dec. 2025 was $802 Mil. CSL's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $3,353 Mil. Therefore, CSL's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 23.92%.
The historical rank and industry rank for CSL's Return-on-Tangible-Equity or its related term are showing as below:
CSLLY'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.85 Med: 70.49 Max: 1451.6
Current: 11.85
During the past 13 years, CSL's highest Return-on-Tangible-Equity was 1,451.60%. The lowest was 11.85%. And the median was 70.49%.
CSLLY's Return-on-Tangible-Equity is ranked better than 87.88% of 1205
companies
in the Biotechnology industry
Industry Median: -42.47
vs CSLLY: 11.85
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
CSL Return-on-Tangible-Equity Related Terms
CSL Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for CSL's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSLLY vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, CSL's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where CSL's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 23.92% mean?
CSL (CSLLY) has a Return-on-Tangible-Equity of 23.92% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CSL and its competitors. This is 66% below median its historical median of 70.49. Over the past decade, CSL's Return-on-Tangible-Equity has ranged from 11.85 to 1,451.60. According to the industry distribution chart, CSL ranks #146 out of 1205 companies in the Biotechnology industry, placing it in the top 12.1%.
Is CSL's Return-on-Tangible-Equity too high?
CSL's current Return-on-Tangible-Equity of 23.92% is 66% below median its 10-year median of 70.49. Over the past 10 years, this metric has ranged from a low of 11.85 to a high of 1,451.60. Based on the distribution chart, CSL ranks #146 out of 1205 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #146 out of 1205 companies for Return-on-Tangible-Equity. This places CSL in the top 12% of its industry — outperforming the majority of peers. Historically, CSL's own Return-on-Tangible-Equity has ranged from 11.85 to 1,451.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CSL and its competitors. CSL's current Return-on-Tangible-Equity is 23.92%, which is 66% below median its own 10-year median of 70.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.49, compared to a current price of $19.98 — trading 60.4% below its estimated fair value. The current Return-on-Tangible-Equity is 23.92%, which is 66% below median its 10-year median of 70.49. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For CSL (CSLLY), the current Return-on-Tangible-Equity is 23.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $19.98 is trading 60.4% below its estimated GF Value™ of $50.49.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
Return-on-Tangible-Equity: 23.92% (66% below median its 10-year median of 70.49)
GF Value™: $50.49 vs. price of $19.98 (60.4% below fair value)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
